Canine Autoimmune Dermatoses: Current Evidence, Diagnostic Challenges and Therapeutic Perspectives
Damini
Department of Veterinary Medicine, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India.
Sushma Chhabra
Department of Veterinary Medicine, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India.
Abrar Ul Haq *
Department of Veterinary Medicine, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India.
*Author to whom correspondence should be addressed.
Abstract
Canine autoimmune skin diseases (AISDs) comprise a complex spectrum of dermatoses resulting from the loss of immunological self-tolerance to epidermal, basement membrane zone or follicular self-antigens. This review critically synthesises current evidence on the immunopathogenesis, diagnostic challenges and evolving therapeutic paradigms of major canine AISDs. These disorders are broadly classified into antibody-mediated acantholytic conditions (the pemphigus complex), subepidermal blistering dermatoses (including bullous pemphigoid and epidermolysis bullosa acquisita) and lymphocyte-driven interface skin diseases (lupus erythematosus variants and canine uveodermatologic syndrome). Accurate diagnosis relies on integrating clinical lesion patterns with skin cytology, histopathology—which identifies key markers such as intraepidermal acantholysis, subepidermal clefting and interface dermatitis—and immunopathological verification using direct and indirect immunofluorescence. Systemic glucocorticoids combined with steroid-sparing immunosuppressants, such as azathioprine, ciclosporin and mycophenolate mofetil, remain the traditional mainstay during the induction, transition and maintenance phases. However, long-term toxicities, refractory cases and variable clinical responses highlight significant management challenges. Emerging targeted immunomodulatory agents—notably Janus kinase (JAK) inhibitors (oclacitinib) and Bruton’s tyrosine kinase (BTK) inhibitors—alongside advanced modalities such as intravenous immunoglobulin, therapeutic plasma exchange and mesenchymal stem-cell therapies, offer safer and more selective alternatives. Major research gaps persist, including reliance on small retrospective cohorts, the lack of standardised disease-activity scores and limited availability of specific immunoserological assays. Addressing these gaps requires prospective, multicentre controlled trials and biomarker-driven studies. Shifting the therapeutic landscape from broad-spectrum immunosuppression towards precision immunotherapy, cytokine-targeted biotherapeutics and antigen-specific tolerance will be vital to optimising long-term management and clinical outcomes in canine dermatology.
Keywords: Canine autoimmune dermatoses, autoimmune blistering diseases, cutaneous lupus erythematosus, immunopathology, direct immunofluorescence, immunosuppressive therapy